IBRX - ImmunityBio, Inc. Stock Price, Fair Value and News

8.61USD+0.49 (+6.03%)Market Closed

Market Summary

USD8.61+0.49

Market Closed

6.03%

IBRX Stock Price

View Fullscreen

IBRX RSI Chart

IBRX Valuation

Market Cap

6.0B

Price/Earnings (Trailing)

-9.91

Price/Sales (Trailing)

19.7K

EV/EBITDA

-12.65

Price/Free Cashflow

-14.42

IBRX Price/Sales (Trailing)

IBRX Profitability

EBT Margin

-199151.99%

Return on Equity

86.98%

Return on Assets

-150%

Free Cashflow Yield

-6.93%

IBRX Fundamentals

IBRX Revenue

Revenue (TTM)

302.0K

Rev. Growth (Yr)

-88.89%

Rev. Growth (Qtr)

-71.22%

IBRX Earnings

Earnings (TTM)

-601.0M

Earnings Growth (Yr)

-15.05%

Earnings Growth (Qtr)

42.46%

Breaking Down IBRX Revenue

Last 7 days

10.2%

Last 30 days

68.5%

Last 90 days

103.6%

Trailing 12 Months

277.6%

How does IBRX drawdown profile look like?

IBRX Financial Health

Current Ratio

3.64

IBRX Investor Care

Shares Dilution (1Y)

58.62%

Diluted EPS (TTM)

-1.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	302.0K	0	0	0
2023	586.0K	592.0K	556.0K	622.0K
2022	760.5K	587.0K	413.5K	240.0K
2021	687.3K	769.5K	851.8K	934.0K
2020	2.4M	2.6M	2.8M	605.0K
2019	585.8K	1.1M	1.7M	2.2M
2018	2.0M	1.4M	701.5K	47.0K
2017	3.0M	2.9M	2.8M	2.7M
2016	3.0M	3.1M	3.1M	3.1M
2015	475.0K	384.0K	364.0K	3.0M
2014	610.3K	620.5K	630.8K	641.0K
2013	0	0	0	600.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ImmunityBio, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 05, 2024	adcock richard	sold (taxes)	-174,387	4.04	-43,165	ceo & president
Feb 05, 2024	adcock richard	acquired	-	-	83,334	ceo & president
Jan 31, 2024	sachs david c.	sold (taxes)	-90,165	3.36	-26,835	chief financial officer
Jan 31, 2024	sachs david c.	acquired	-	-	70,745	chief financial officer
Jan 31, 2024	simon barry j.	sold (taxes)	-74,235	3.36	-22,094	-
Jan 31, 2024	simon barry j.	acquired	-	-	57,200	-
Jan 31, 2024	lauer regan j	sold (taxes)	-45,259	3.36	-13,470	chief accounting officer
Jan 31, 2024	lauer regan j	acquired	-	-	32,872	chief accounting officer
Dec 31, 2023	adcock richard	acquired	-	-	34,483	ceo & president
Dec 31, 2023	adcock richard	sold (taxes)	-85,821	5.02	-17,096	ceo & president

Which funds bought or sold IBRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	OSAIC HOLDINGS, INC.	added	41.28	78,403	231,751	-%
May 10, 2024	PNC Financial Services Group, Inc.	reduced	-49.16	-4,658	5,553	-%
May 10, 2024	CITIGROUP INC	added	261	4,493,400	6,059,760	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	4.54	30,501	288,287	-%
May 10, 2024	VANGUARD GROUP INC	added	1.58	5,798,400	72,707,600	-%
May 10, 2024	JPMORGAN CHASE & CO	added	0.95	570,452	7,709,960	-%
May 10, 2024	BlackRock Inc.	reduced	-3.13	1,950,320	55,715,400	-%
May 10, 2024	LPL Financial LLC	added	42.19	111,607	325,825	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	32,741	32,741	-%
May 10, 2024	Covestor Ltd	reduced	-55.13	-	-	-%

Are Funds Buying or Selling IBRX?

Are funds buying IBRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IBRX

No. of Funds

Unveiling ImmunityBio, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 04, 2024	cambridge equities, lp	39.0%	261,705,814	SC 13D/A
Sep 21, 2023	cambridge equities, lp	39.2%	261,705,814	SC 13D/A
May 23, 2023	cambridge equities, lp	60.0%	261,705,814	SC 13D/A
Dec 07, 2022	cambridge equities, lp	65.4%	261,705,814	SC 13D/A

Recent SEC filings of ImmunityBio, Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 02, 2024	EFFECT	EFFECT
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	ARS	ARS
Apr 23, 2024	8-K	Current Report
Apr 17, 2024	S-3ASR	S-3ASR
Mar 29, 2024	S-3	S-3
Mar 19, 2024	10-K	Annual Report
Feb 26, 2024	8-K	Current Report

Peers (Alternatives to ImmunityBio, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

ImmunityBio, Inc. News

Latest updates

ImmunityBio, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-71.2%	40,000	139,000	82,000	41,000	360,000	73,000	118,000	35,000	212,500	390,000	66,000	339,000	139,000	145,000	151,000	436,000	78,000	2,168,000	1,627,750	1,087,500	547,250
Operating Expenses	11.4%	95,236,000	85,528,000	80,218,000	85,186,000	111,940,000	84,973,000	90,922,000	79,657,000	95,986,000	79,664,000	78,902,000	86,245,000	86,403,000	30,907,000	66,028,000	51,352,000	36,867,000	16,120,000	16,077,000	17,313,000	18,340,000
S&GA Expenses	26.5%	41,885,000	33,110,000	31,816,000	32,018,000	32,676,000	26,215,000	19,310,000	16,575,000	40,608,000	27,911,000	29,625,000	32,445,000	45,275,000	23,882,000	19,596,000	18,347,000	9,493,000	32,507,000	4,025,000	4,182,000	5,742,000
R&D Expenses	3.5%	53,351,000	51,532,000	48,402,000	53,168,000	79,264,000	58,077,000	71,612,000	63,082,000	55,378,000	51,753,000	49,277,000	53,800,000	41,128,000	43,356,000	35,772,000	33,005,000	27,374,000	74,216,000	12,052,000	13,131,000	12,598,000
EBITDA Margin	-117.1%	-1,523	-702	-565	-588	-559	-1,399	-835	-572	-442	-343	-352	-366	-	-	-	-	-	-	-	-	-
Interest Expenses	-25.6%	23,912,000	32,126,000	35,021,000	32,235,000	29,816,000	28,562,000	16,764,000	9,698,000	8,491,000	4,490,000	3,614,000	3,577,000	3,168,000	2,836,000	2,226,000	2,123,000	1,889,000	5,912,000	5,000	-	3,000
Income Taxes	100.0%	-	-40,000	-	-	-	34,000	-	-	-	1,000	-	2,000	6,000	-209,000	-1,700,000	45,000	18,000	-71,000	-	2,000	-36,000
Earnings Before Taxes	42.5%	-134,130,000	-233,454,000	-95,642,000	-138,213,000	-116,583,000	-108,292,000	-111,161,000	-94,835,000	-102,998,000	-91,552,000	-88,429,000	-89,383,000	-80,475,000	-68,782,000	-67,870,000	-51,972,000	-37,409,000	-110,081,000	-15,581,000	-16,680,000	-17,921,000
EBT Margin	-112.1%	-1,991	-938	-825	-801	-735	-1,738	-968	-643	-489	-374	-384	-398	-	-	-	-	-	-	-	-	-
Net Income	42.5%	-134,130,000	-233,105,000	-95,582,000	-138,213,000	-116,583,000	-108,005,500	-110,938,000	-94,835,000	-102,998,000	-90,277,000	-87,629,000	-89,385,000	-80,481,000	-32,132,000	-65,603,000	-51,439,000	-37,038,000	-15,641,000	-15,581,000	-16,682,000	-17,885,000
Net Income Margin	-112.2%	-1,990	-938	-824	-800	-734	-1,736	-965	-640	-486	-372	-340	-347	-	-	-	-	-	-	-	-	-
Free Cashflow	12.2%	-108,243,000	-123,226,000	-93,061,000	-88,326,000	-92,728,000	-109,658,000	-96,535,000	-107,201,000	-102,277,000	-82,042,000	-80,748,000	-77,640,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-20.6%	401	504	432	291	343	362	353	318	390	469	214	246	209	221	181	196	127	270	160	176	208
Current Assets	-33.4%	196	294	215	67.00	113	141	143	115	212	334	94.00	114	100	112	98.00	115	44.00	131	72.00	87.00	113
Cash Equivalents	-49.9%	133	265	178	44.00	88.00	105	104	62.00	36.00	181	65.00	84.00	45.00	35.00	85.00	115	59.00	76.00	18.00	17.00	22.00
Net PPE	-1.8%	144	146	152	151	154	144	130	119	105	83.00	70.00	89.00	81.00	73.00	56.00	59.00	59.00	83.00	62.00	65.00	68.00
Liabilities	0.1%	1,092	1,090	843	936	875	812	782	740	727	713	404	405	395	340	32.00	27.00	24.00	253	24.00	24.00	40.00
Current Liabilities	-7.8%	54.00	58.00	90.00	613	565	501	71.00	376	381	369	65.00	74.00	80.00	68.00	21.00	17.00	14.00	48.00	13.00	12.00	28.00
Shareholder's Equity	-17.9%	-690	-585	-	-	-531	-449	-	-	-	-243	-	-	-	117	149	14.00	103	16.00	136	151	168
Retained Earnings	-4.7%	-3,100	-2,961	-2,728	-2,632	-2,500	-2,378	-2,270	-2,159	-2,064	-1,961	-1,870	-1,800	-1,694	-1,615	-722	-700	-680	-1,393	-646	-630	-613
Additional Paid-In Capital	1.2%	2,404	2,375	2,316	1,991	1,966	1,931	1,844	1,740	1,729	1,720	1,682	1,625	1,509	1,495	871	870	783	1,406	783	782	782
Accumulated Depreciation	4.8%	88.00	84.00	81.00	78.00	73.00	69.00	65.00	61.00	57.00	53.00	50.00	48.00	45.00	42.00	25.00	23.00	21.00	28.00	16.00	14.00	12.00
Shares Outstanding	0.9%	677	671	668	441	422	422	399	398	398	389	387	384	-	-	-	-	-	-	-	-	-
Minority Interest	-2.0%	1.00	1.00	1.00	-3.07	-2.73	-2.49	-2.38	-2.16	-1.91	-1.74	-1.45	-0.65	0.00	1.00	-	-	-	-	-	-	-
Float	-	-	-	-	316	-	-	-	302	-	-	-	1,051	-	-	-	415	-	-	-	29.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	7.2%	-106,982	-115,271	-87,386	-79,800	-84,300	-90,727	-80,600	-91,252	-74,930	-71,639	-72,716	-69,595	-60,469	-57,604	-36,991	-46,022	-31,107	-105,632	-16,572	-16,827	-13,078
Share Based Compensation	-35.3%	8,266	12,774	14,449	11,062	10,878	9,350	10,630	10,175	10,024	10,180	13,840	17,863	15,298	671	714	322	480	1,271	277	522	1,351
Cashflow From Investing	-1683.9%	-35,622	2,249	-15,631	-8,604	-8,484	-18,894	-1,168	116,672	-69,313	-137,802	10,582	10,489	31,845	7,545	-56,625	15,274	13,994	9,259	17,374	11,378	-19,459
Cashflow From Financing	-94.9%	10,225	200,539	237,502	43,412	76,888	109,940	123,986	-15.00	-298	325,953	42,656	98,337	38,497	241	63,217	87,340	-123	75,625	-40.00	-501	39,195
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,000	-	501	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IBRX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 40	$ 360
Operating expenses:
Research and development (including amounts with related parties)	53,351	79,264
Selling, general and administrative (including amounts with related parties)	41,885	32,676
Total operating expenses	95,236	111,940
Loss from operations	(95,196)	(111,580)
Other expense, net:
Interest and investment income, net	3,099	673
Interest expense (including amounts with related parties)	(29,483)	(29,816)
Loss on equity method investment	0	(2,337)
Change in fair value of warrant liabilities	(1,802)	27,554
Change in fair value of derivative liabilities	(2,724)	0
Interest expense related to revenue interest liability	(8,004)	0
Other expense, net (including amounts with related parties)	(20)	(1,077)
Total other expense, net	(38,934)	(5,003)
Loss before income taxes and noncontrolling interests	(134,130)	(116,583)
Income tax expense	0	0
Net loss	(134,130)	(116,583)
Net loss attributable to noncontrolling interests, net of tax	(21)	(240)
Net loss attributable to ImmunityBio common stockholders	$ (134,109)	$ (116,343)
Net loss per ImmunityBio common share – basic (in dollars per share)	$ (0.20)	$ (0.27)
Net loss per ImmunityBio common share - diluted (in dollars per share)	$ (0.20)	$ (0.27)
Weighted-average number of common shares used in computing net loss per share – basic (in shares)	672,831,258	428,381,485
Weighted-average number of common shares used in computing net loss per share – diluted (in shares)	672,831,258	428,381,485

IBRX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 133,035	$ 265,453
Marketable securities	37,460	1,009
Due from related parties	2,137	2,019
Prepaid expenses and other current assets (including amounts with related parties)	23,090	25,603
Total current assets	195,722	294,084
Marketable securities, noncurrent	0	891
Property, plant and equipment, net	143,517	146,082
Intangible assets, net	16,572	17,093
Convertible note receivable	6,942	6,879
Operating lease right-of-use assets, net (including amounts with related parties)	35,197	36,543
Other assets (including amounts with related parties)	2,729	2,880
Total assets	400,679	504,452
Current liabilities:
Accrued expenses and other liabilities	32,712	42,708
Operating lease liabilities (including amounts with related parties)	6,082	5,244
Total current liabilities	53,759	58,283
Related-party nonconvertible note, net of discount (Note 10)	106,637	104,586
Related-party convertible notes and accrued interest, net of discount (Note 10)	580,449	576,951
Revenue interest liability (Note 9)	163,416	155,415
Operating lease liabilities, less current portion (including amounts with related parties)	38,199	39,942
Derivative liabilities (Note 9) and (Note 10)	37,930	35,333
Warrant liabilities	109,987	118,770
Other liabilities	1,285	1,109
Total liabilities	1,091,662	1,090,389
Commitments and contingencies (Note 7)
Stockholders’ deficit:
Common stock, $0.0001 par value; 1,350,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 677,003,411 and 670,867,344 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively; excluding treasury stock, 163,800 shares outstanding as of March 31, 2024 and December 31, 2023	68	67
Additional paid-in capital	2,403,720	2,374,620
Accumulated deficit	(3,095,793)	(2,961,684)
Accumulated other comprehensive (loss) income	(7)	10
Total ImmunityBio stockholders’ deficit	(692,012)	(586,987)
Noncontrolling interests	1,029	1,050
Total stockholders’ deficit	(690,983)	(585,937)
Total liabilities and stockholders’ deficit	400,679	504,452
Non-related Party
Current liabilities:
Accounts payable	13,869	9,195
Related Party
Current assets:
Due from related parties	2,137	2,019
Current liabilities:
Accounts payable	$ 1,096	$ 1,136

About ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.

CEO	Mr. Richard Gerald Adcock
WEBSITE	https://immunitybio.com
INDUSTRY	Biotechnology
EMPLOYEES	683

ImmunityBio, Inc. Frequently Asked Questions

What is the ticker symbol for ImmunityBio, Inc.? What does IBRX stand for in stocks?

IBRX is the stock ticker symbol of ImmunityBio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ImmunityBio, Inc. (IBRX)?

As of Mon May 13 2024, market cap of ImmunityBio, Inc. is 5.95 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IBRX stock?

You can check IBRX's fair value in chart for subscribers.

What is the fair value of IBRX stock?

You can check IBRX's fair value in chart for subscribers. The fair value of ImmunityBio, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ImmunityBio, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IBRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ImmunityBio, Inc. a good stock to buy?

The fair value guage provides a quick view whether IBRX is over valued or under valued. Whether ImmunityBio, Inc. is cheap or expensive depends on the assumptions which impact ImmunityBio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IBRX.

What is ImmunityBio, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, IBRX's PE ratio (Price to Earnings) is -9.91 and Price to Sales (PS) ratio is 19.72 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IBRX PE ratio will change depending on the future growth rate expectations of investors.